{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:13:07Z","timestamp":1791598387489,"version":"4.3.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015739","name":"Bayer Vital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015739","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40273-025-01524-w","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T09:59:50Z","timestamp":1753523990000},"page":"1223-1233","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Challenges and Criteria for Single-Arm Trials Leading to an Added Benefit in German Health Technology Assessments"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2147-1366","authenticated-orcid":false,"given":"J\u00f6rg","family":"Tomeczkowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8093-0165","authenticated-orcid":false,"given":"Tanja","family":"Heidbrede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birte","family":"Eichinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Osowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7218-1272","authenticated-orcid":false,"given":"Friedhelm","family":"Leverkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Schmitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3469-092X","authenticated-orcid":false,"given":"Charalabos-Markos","family":"Dintsios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,26]]},"reference":[{"key":"1524_CR1","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1002\/pst.2120","volume":"20","author":"HU Burger","year":"2021","unstructured":"Burger HU, Gerlinger C, Harbron C, Koch A, Posch M, Rochon J, et al. The use of external controls: To what extent can it currently be recommended? Pharm Stat. 2021;20:1002\u201316.","journal-title":"Pharm Stat"},{"key":"1524_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40273-017-0596-z","volume":"36","author":"A Makady","year":"2018","unstructured":"Makady A, van Veelen A, Jonsson P, Moseley O, D\u2019Andon A, de Boer A, et al. Using real-world data in health technology assessment (HTA) practice: a comparative study of five HTA agencies. Pharmacoeconomics. 2018;36:359\u201368.","journal-title":"Pharmacoeconomics"},{"key":"1524_CR3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/cpt.1638","volume":"107","author":"H Eichler","year":"2020","unstructured":"Eichler H, Koenig F, Arlett P, Enzmann H, Humphreys A, P\u00e9tavy F, et al. Are novel, nonrandomized analytic methods fit for decision making? The need for prospective, controlled, and transparent validation. Clin Pharmacol Ther. 2020;107:773\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"1524_CR4","unstructured":"European Medicines Agency. Clinical efficacy and safety guidelines. London: EMA. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/scientific-guidelines\/clinical-efficacy-safety-guidelines (Accessed 26 April 2025)"},{"key":"1524_CR5","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1002\/cpt.2083","volume":"109","author":"H Eichler","year":"2021","unstructured":"Eichler H, Pignatti F, Schwarzer-Daum B, Hidalgo-Simon A, Eichler I, Arlett P, et al. Randomized controlled trials versus real world evidence: neither magic nor myth. Clin Pharmacol Ther. 2021;109:1212\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"1524_CR6","unstructured":"European Medicines Agency. ICH E11(R1) guideline on clinical investigation of medicinal products in the pediatric population - Scientific guideline. London: EMA; 2018. https:\/\/www.ema.europa.eu\/en\/ich-e11r1-guideline-clinical-investigation-medicinal-products-pediatric-population-scientific-guideline (Accessed 26 April 2025)"},{"issue":"2","key":"1524_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101209","volume":"8","author":"J Mulder","year":"2023","unstructured":"Mulder J, Teerenstra S, van Hennik PB, Pasmooij AMG, Stoyanova-Beninska V, Voest EE, et al. Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit. ESMO Open. 2023;8(2): 101209. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101209.","journal-title":"ESMO Open."},{"key":"1524_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011666","volume":"6","author":"AJ Hatswell","year":"2016","unstructured":"Hatswell AJ, Baio G, Berlin JA, Irs A, Freemantle N. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999\u20132014. BMJ Open. 2016;6: e011666.","journal-title":"BMJ Open"},{"key":"1524_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024895","volume":"9","author":"S Goring","year":"2019","unstructured":"Goring S, Taylor A, M\u00fcller K, Li TJJ, Korol EE, Levy AR, et al. Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review. BMJ Open. 2019;9: e024895.","journal-title":"BMJ Open"},{"key":"1524_CR10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jclinepi.2022.01.018","volume":"148","author":"TB Ribeiro","year":"2022","unstructured":"Ribeiro TB, Colunga-Lozano LE, Araujo APV, Bennett CL, Hozo I, Djulbegovic B. Single-arm clinical trials that supported FDA accelerated approvals have modest effect sizes and were at high risk of bias. J Clin Epidemiol. 2022;148:193\u20135.","journal-title":"J Clin Epidemiol"},{"key":"1524_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2023.100403","volume":"35","author":"X Wang","year":"2023","unstructured":"Wang X, Dormont F, Lorenzato C, Latouche A, Hernandez R, Rouzier R. Current perspectives for external control arms in oncology clinical trials: analysis of EMA approvals 2016\u20132021. J Cancer Policy. 2023;35: 100403.","journal-title":"J Cancer Policy"},{"key":"1524_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13023-024-03095-z","volume":"19","author":"L Bouwman","year":"2024","unstructured":"Bouwman L, Sepodes B, Leufkens H, Torre C. Trends in orphan medicinal products approvals in the European Union between 2010\u20132022. Orphanet J Rare Dis. 2024;19:91. https:\/\/doi.org\/10.1186\/s13023-024-03095-z.","journal-title":"Orphanet J Rare Dis"},{"key":"1524_CR13","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1517\/21678707.2016.1166950","volume":"4","author":"M Bouslouk","year":"2016","unstructured":"Bouslouk M. G-BA benefit assessment of new orphan drugs in Germany: the first five years. Expert Opin Orphan Drugs. 2016;4:453\u20135.","journal-title":"Expert Opin Orphan Drugs"},{"key":"1524_CR14","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1177\/0272989X14546377","volume":"34","author":"KE Fischer","year":"2014","unstructured":"Fischer KE, Stargardt T. Early benefit assessment of pharmaceuticals in Germany. Med Decis Making. 2014;34:1030\u201347.","journal-title":"Med Decis Making"},{"key":"1524_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.healthpol.2013.12.008","volume":"116","author":"H H\u00f6rn","year":"2014","unstructured":"H\u00f6rn H, Nink K, McGauran N, Wieseler B. Early benefit assessment of new drugs in Germany\u2014results from 2011 to 2012. Health Policy (New York). 2014;116:147\u201353.","journal-title":"Health Policy (New York)."},{"key":"1524_CR16","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s10198-013-0495-y","volume":"15","author":"J Ruof","year":"2014","unstructured":"Ruof J, Schwartz FW, Schulenburg J-M, Dintsios C-M. Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation. Eur J Health Econ. 2014;15:577\u201389.","journal-title":"Eur J Health Econ"},{"key":"1524_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/bimj.201300274","volume":"58","author":"G Skipka","year":"2016","unstructured":"Skipka G, Wieseler B, Kaiser T, Thomas S, Bender R, Windeler J, et al. Methodological approach to determine minor, considerable, and major treatment effects in the early benefit assessment of new drugs. Biometr J. 2016;58:43\u201358.","journal-title":"Biometr J."},{"key":"1524_CR18","unstructured":"Institute for Quality and Efficiency in Health Care (Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen) (IQWiG). General Methods 7.0. 2023. https:\/\/www.iqwig.de\/en\/about-us\/methods\/methods-paper\/ (Accessed 2 July 2025)"},{"key":"1524_CR19","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jval.2017.04.006","volume":"20","author":"VD Lauenroth","year":"2017","unstructured":"Lauenroth VD, Stargardt T. Pharmaceutical pricing in Germany: how is value determined within the scope of AMNOG? Value Health. 2017;20:927\u201335.","journal-title":"Value Health."},{"key":"1524_CR20","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s10198-020-01201-z","volume":"21","author":"A Gandjour","year":"2020","unstructured":"Gandjour A, Sch\u00fc\u00dfler S, Hammerschmidt T, Dintsios C-M. Predictors of negotiated prices for new drugs in Germany. Eur J Health Econ. 2020;21:1049\u201357.","journal-title":"Eur J Health Econ"},{"key":"1524_CR21","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40273-019-00872-8","volume":"38","author":"F Worm","year":"2020","unstructured":"Worm F, Dintsios C-M. Determinants of orphan drug prices in Germany. Pharmacoeconomics. 2020;38:397\u2013411.","journal-title":"Pharmacoeconomics"},{"key":"1524_CR22","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.jval.2016.05.016","volume":"19","author":"S Ludwig","year":"2016","unstructured":"Ludwig S, Dintsios C-M. Arbitration board setting reimbursement amounts for pharmaceutical innovations in Germany when price negations between payers and manufacturers fail: an empirical analysis of 5 years\u2019 experience. Value Health. 2016;19:1016\u201325.","journal-title":"Value Health."},{"key":"1524_CR23","doi-asserted-by":"publisher","DOI":"10.1017\/S026646232300048X","volume":"39","author":"G Casilli","year":"2023","unstructured":"Casilli G, Lidonnici D, Jommi C, De Nigris M, Genazzani AA. Do France, Germany, and Italy agree on the added therapeutic value of medicines? Int J Technol Assess Health Care. 2023;39: e54.","journal-title":"Int J Technol Assess Health Care"},{"key":"1524_CR24","unstructured":"Aerztezeitung. Hecken: Fr\u00fche Nutzenbewertung passt nicht mehr zu den neuen Wirkstoffen. https:\/\/www.aerztezeitung.de\/Politik\/Hecken-Fruehe-Nutzenbewertung-passt-nicht-mehr-zu-den-neuen-Wirkstoffen-456149.html (Accessed 27 April 2025)"},{"key":"1524_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13561-019-0254-6","volume":"9","author":"CM Dintsios","year":"2019","unstructured":"Dintsios CM, Worm F, Ruof J, Herpers M. Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree. Health Econ Rev. 2019;9:35.","journal-title":"Health Econ Rev."},{"key":"1524_CR26","unstructured":"Hankowitz J. AMNOG | Germany\u2019s early benefit assessments in detail: AMNOG-Monitor. https:\/\/www.amnog-monitor.com\/ (Accessed 27 April 2025)"},{"key":"1524_CR27","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/(SICI)1097-0258(19960330)15:6<631::AID-SIM206>3.0.CO;2-6","volume":"15","author":"JF Hilton","year":"1996","unstructured":"Hilton JF. The appropriateness of the Wilcoxon test in ordinal data. Stat Med. 1996;15:631\u201345.","journal-title":"Stat Med"},{"key":"1524_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/pri.66","volume":"1","author":"MR Sheldon","year":"1996","unstructured":"Sheldon MR, Fillyaw MJ, Thompson WD. The use and interpretation of the Friedman test in the analysis of ordinal-scale data in repeated measures designs. Physiother Res Int. 1996;1:221\u20138.","journal-title":"Physiother Res Int"},{"key":"1524_CR29","unstructured":"Federal Joint Committee (Gemeinsamer Bundesausschuss). AIS \u2013 Maschinenlesbare Fassung der Beschl\u00fcsse zur Nutzenbewertung von Arzneimitteln gem\u00e4\u00df \u00a7 35a SGB V - Gemeinsamer Bundesausschuss. https:\/\/www.g-ba.de\/themen\/arzneimittel\/arzneimittel-richtlinie-anlagen\/nutzenbewertung-35a\/ais\/ (Accessed 2 July 2025)"},{"key":"1524_CR30","unstructured":"Federal Joint Committee (Gemeinsamer Bundesausschuss). Verfahrensordnung des Gemeinsamen Bundesausschusses. https:\/\/www.g-ba.de\/richtlinien\/42\/ (Accessed 27 April 2025)"},{"key":"1524_CR31","unstructured":"Federal Joint Committee (Gemeinsamer Bundesausschuss). Tragende Gr\u00fcnde zum Beschluss des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII-Beschl\u00fcsse \u00fcber die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach \u00a7 35a SGB V-Ledipasvir\/Sofosbuvir. 2015. https:\/\/www.g-ba.de\/downloads\/40-268-3225\/2015-05-21_AM-RL-XII_Ledipasvir-Sofosbuvir_2014-12-01-D-143_TrG.pdf (Accessed 2 July 2025)"},{"key":"1524_CR32","unstructured":"Federal Joint Committe (Gemeinsamer Bundesausschuss). Tragende Gr\u00fcnde zum Beschluss des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII-Beschl\u00fcsse \u00fcber die Nutzenbewer-tung von Arzneimitteln mit neuen Wirkstoffen nach \u00a7 35a SGB V-Ledipasvir\/Sofosbuvir (neues Anwendungsgebiet: Chronische Hepatitis C bei Jugendlichen). 2018. https:\/\/www.g-ba.de\/downloads\/40-268-4805\/2018-02-15_AM-RL-XII_Ledipasvir-Sofosbuvir-nAWG_D-304_TrG.pdf (Accessed 2 July 2025)"},{"key":"1524_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s41669-023-00455-6","volume":"8","author":"B Macabeo","year":"2024","unstructured":"Macabeo B, Rotrou T, Millier A, Fran\u00e7ois C, Laram\u00e9e P. The acceptance of indirect treatment comparison methods in oncology by health technology assessment agencies in England, France, Germany, Italy, and Spain. Pharmacoecon Open. 2024;8:5\u201318.","journal-title":"Pharmacoecon Open."},{"key":"1524_CR34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/cpt.3296","volume":"117","author":"J Tomeczkowski","year":"2025","unstructured":"Tomeczkowski J, Heidbrede T, Leverkus F, Schmitter S, Dintsios C, Osowski U, et al. Questioning conclusions and statements on the German HTA system: a critical perspective. Clin Pharmacol Ther. 2025;117:22\u20133.","journal-title":"Clin Pharmacol Ther"},{"issue":"12 suppl","key":"1524_CR35","doi-asserted-by":"publisher","first-page":"S300","DOI":"10.1016\/j.jval.2022.09.1484","volume":"25","author":"J Tomeczkowski","year":"2022","unstructured":"Tomeczkowski J, Partemio G, Nijhuis T, Kubitz N, Kavanagh S. HTA 24 Real-world data as external controls for single-arm trials: Role in regulatory and health technology assessments [abstract]. Value Health. 2022;25(12 suppl):S300-301. https:\/\/doi.org\/10.1016\/j.jval.2022.09.1484.","journal-title":"Value Health."},{"key":"1524_CR36","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.jval.2021.01.015","volume":"24","author":"D Patel","year":"2021","unstructured":"Patel D, Grimson F, Mihaylova E, Wagner P, Warren J, van Engen A, et al. Use of external comparators for health technology assessment submissions based on single-arm trials. Value Health. 2021;24:1118\u201325.","journal-title":"Value Health."},{"key":"1524_CR37","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/cpt.2914","volume":"114","author":"O Sola-Morales","year":"2023","unstructured":"Sola-Morales O, Curtis LH, Heidt J, Walsh L, Casso D, Oliveria S, et al. Effectively leveraging RWD for external controls: a systematic literature review of regulatory and HTA decisions. Clin Pharmacol Ther. 2023;114:325\u201355.","journal-title":"Clin Pharmacol Ther"},{"key":"1524_CR38","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.jval.2022.01.014","volume":"25","author":"O Cox","year":"2022","unstructured":"Cox O, Sammon C, Simpson A, Wasiak R, Ramagopalan S, Thorlund K. The (harsh) reality of real-world data external comparators for health technology assessment. Value Health. 2022;25:1253\u20136.","journal-title":"Value Health."},{"key":"1524_CR39","unstructured":"Federal Joint Committee (Gemeinsamer Bundesausschuss). Nutzenbewertungsverfahren zum Wirkstoff Simeprevir (Chronische Hepatitis C). 2014. https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/118\/#nutzenbewertung (Accessed 27 April 2025)"},{"key":"1524_CR40","unstructured":"European Medicines Agency (EMA). ICH E10 Choice of control group in clinical trials - Scientific guideline. https:\/\/www.ema.europa.eu\/en\/ich-e10-choice-control-group-clinical-trials-scientific-guideline (Accessed 27 April 2025)"},{"key":"1524_CR41","first-page":"349","volume":"334","author":"P Glasziou","year":"2007","unstructured":"Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomised trials unnecessary? Picking signal from noise BMJ. 2007;334:349\u201351.","journal-title":"Picking signal from noise. BMJ."},{"key":"1524_CR42","unstructured":"Federal Joint Committee (Gemeinsamer Bundesausschuss). Nutzenbewertungsverfahren zum Wirkstoff Amivantamab (Nicht-kleinzelliges Lungenkarzinom, EGFR-Exon-20-Insertionsmutation, nach platinbasierter Therapie). 2022. https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/783\/#english (Accessed 27 April 2025)"},{"key":"1524_CR43","unstructured":"Bucher H. Assessment of the added benefit of pharmaceuticals without RCT \u2013 a case study. https:\/\/r-connect.org\/IPoBA%20Volume%2016.pdf. 2023. https:\/\/r-connect.org\/ipoba.html (Accessed 27 April 2025)"},{"key":"1524_CR44","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1007\/s43441-024-00693-8","volume":"58","author":"D Subramaniam","year":"2024","unstructured":"Subramaniam D, Anderson-Smits C, Rubinstein R, Thai ST, Purcell R, Girman C. A framework for the use and likelihood of regulatory acceptance of single-arm trials. Ther Innov Regul Sci. 2024;58:1214\u201332.","journal-title":"Ther Innov Regul Sci."},{"issue":"1","key":"1524_CR45","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12325-024-03013-6","volume":"42","author":"A Igarashi","year":"2025","unstructured":"Igarashi A, Tanaka S, De Moor R, Li N, Hirozane M, Wu DBC, et al. Indirect treatment comparisons in healthcare decision making: a targeted review of regulatory approval, reimbursement, and pricing recommendations globally for oncology drugs in 2021\u20132023. Adv Ther. 2025;42(1):52\u201369. https:\/\/doi.org\/10.1007\/s12325-024-03013-6.","journal-title":"Adv Ther"},{"key":"1524_CR46","doi-asserted-by":"publisher","unstructured":"Tomeczkowski J, Leverkus F, Bussilliat P, Osowski U, Herrmann KH, Eichinger B, et al. Letter to the Editor Regarding \u201cIndirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021\u20132023.\u201d [online ahead of print]. Adv Ther. 2025 Jun 20; https:\/\/doi.org\/10.1008\/s12325-025-03269-6.","DOI":"10.1008\/s12325-025-03269-6"},{"key":"1524_CR47","unstructured":"Federal Joint Committee (Gemeinsamer Bundesausschuss). Nutzenbewertungsverfahren zum Wirkstoff Asfotase alfa (\u00dcberschreitung 50 Mio. \u20ac Grenze: Hypophosphatasie). 2020. https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/505\/#english (Accessed 27 April 2025)"},{"key":"1524_CR48","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/10543406.2021.2011902","volume":"32","author":"A Sachdeva","year":"2022","unstructured":"Sachdeva A, Tiwari RC, Guha S. A novel approach to augment single-arm clinical studies with real-world data. J Biopharm Stat. 2022;32:141\u201357.","journal-title":"J Biopharm Stat"},{"key":"1524_CR49","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1080\/10543406.2019.1657132","volume":"29","author":"F Jiao","year":"2019","unstructured":"Jiao F, Tu W, Jimenez S, Crentsil V, Chen Y-F. Utilizing shared internal control arms and historical information in small-sized platform clinical trials. J Biopharm Stat. 2019;29:845\u201359.","journal-title":"J Biopharm Stat"},{"key":"1524_CR50","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1080\/10543406.2021.2011901","volume":"32","author":"X Yin","year":"2022","unstructured":"Yin X, Mishra-Kalyan PS, Sridhara R, Stewart MD, Stuart EA, Davi RC. Exploring the potential of external control arms created from patient level data: a case study in non-small cell lung cancer. J Biopharm Stat. 2022;32:204\u201318.","journal-title":"J Biopharm Stat"},{"key":"1524_CR51","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s40264-020-00944-1","volume":"43","author":"CM Gray","year":"2020","unstructured":"Gray CM, Grimson F, Layton D, Pocock S, Kim J. A framework for methodological choice and evidence assessment for studies using external comparators from real-world data. Drug Saf. 2020;43:623\u201333.","journal-title":"Drug Saf"},{"key":"1524_CR52","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13023-020-1332-x","volume":"15","author":"M Ghadessi","year":"2020","unstructured":"Ghadessi M, Tang R, Zhou J, Liu R, Wang C, Toyoizumi K, et al. A roadmap to using historical controls in clinical trials\u2014by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG). Orphanet J Rare Dis. 2020;15:69.","journal-title":"Orphanet J Rare Dis"},{"key":"1524_CR53","unstructured":"Federal Joint Committee (Gemeinsamer Bundesausschuss). Beauftragung IQWiG: Wissenschaftliche Ausarbeitung zur Methodik im Bereich der anwendungsbegleitenden Datenerhebung [Internet]. 2025. https:\/\/www.g-ba.de\/beschluesse\/7056\/ (Accessed 27 April 2025)"},{"key":"1524_CR54","doi-asserted-by":"crossref","unstructured":"Vanier A, Fernandez J, Kelley S, Alter L, Semenzato P, Alberti C, et al. Rapid access to innovative medicinal products while ensuring relevant health technology assessment. Position of the French National Authority for Health. BMJ Evid Based Med. 2024;29:1\u20135.","DOI":"10.1136\/bmjebm-2022-112091"},{"key":"1524_CR55","unstructured":"Haute Autorit\u00e9 de sant\u00e9 (HAS). Commission de la transparence CT Rapport d\u2019activit\u00e9 2023. 2023; p. 28. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2024-06\/rapport_dactivite_2023_de_la_ct.pdf (Accessed 31 May 2025)"},{"key":"1524_CR56","doi-asserted-by":"crossref","unstructured":"Tomeczkowski J, Herrmann KH. Enhancing the acceptance of externally controlled trials (ECTs) in the German HTA System: analysis of guidance documents from other countries. 2024. https:\/\/www.researchgate.net\/publication\/385903423_Enhancing_the_Acceptance_of_Externally_Controlled_Trials_ECTs_in_the_German_HTA_System_Analysis_of_Guidance_Documents_From_Other_Countries (Accessed 27 April 2025)","DOI":"10.1016\/j.jval.2024.10.1501"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01524-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01524-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01524-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:51:51Z","timestamp":1758361911000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01524-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,26]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1524"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01524-w","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,26]]},"assertion":[{"value":"7 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"An unrestricted grant was received from Novartis Pharma GmbH and Bayer Vital GmbH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"J\u00f6rg Tomeczkowski, Tanja Heidbrede, Birte Eichinger, Ulrike Osowski, Friedhelm Leverkus, Sarah Schmitter, and Charalabos-Markos Dintsios have no competing interests relevant to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All the data included in the analysis are available in the AMNOG-Monitor database and are publicly available on the IQWiG and G-BA websites.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"J\u00f6rg Tomeczkowski, Sarah Schmitter and Charalabos-Markos Dintsios contributed to the concept and design, statistical analysis, and drafting of the manuscript. Friedhelm Leverkus, Tanja Heidbrede, Birte Eichinger, and Ulrike Osowski, drafted the manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contribution"}}]}}